What people report
Semaglutide reviews: what people report
Read 41 people, 3 sitesPublished by PepVault
Of the 41 people whose Semaglutide write-ups we read, 33 describe a change they wanted (33 a change in weight or appetite; 2 a calmer gut), 1 noticed nothing and 28 describe something unwanted.
What people report
33 of the 41 people describe at least one change they wanted. Each bar counts the people who named anything in that group, once each, out of all 41; the line under it says what they named, and how many named it. Each took it on its own.
What went wrong or did nothing
28 of the 41 people describe something they didn’t want, and 1 noticed nothing at all.
Your report
Taken Semaglutide? What did you notice?
One tap to start. About 30 seconds, no account.

When people say it begins
6 of the 41 people say when they first noticed something; 35 don’t.
What people took it for
22 of the 41 people say what they took it for; 19 don’t.
How it’s thought to work
Shown in people
Semaglutide is a long-lasting copy of GLP-1, a gut hormone released after a meal. It slows the stomach, makes a meal fill you sooner, quiets hunger in the brain and helps the pancreas release insulin when blood sugar rises. Controlled trials in people showed it lowers body weight, blood sugar and the risk of heart attacks and strokes; it is approved as Ozempic and Rybelsus for type two diabetes and as Wegovy for weight loss.
Sources: Wilding et al., 2021: STEP 1, weight in adults without diabetes; Marso et al., 2016: SUSTAIN-6, heart events in type two diabetes; Lincoff et al., 2023: SELECT, heart events in obesity without diabetes
What studies show
Our research section has 31 study pages on Semaglutide: 30 in people and 1 in mice.
The first large trial for weight loss gave 1961 adults without diabetes a weekly shot of semaglutide or a dummy shot for 68 weeks (STEP 1); their weight fell by 14.9% on average, against 2.4% on the dummy shot, and nausea and diarrhea were the commonest side effects.
- Semaglutide: 11.85% more weight loss than placebo without diabetes
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5
- CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3
- Semaglutide (oral) did not slow early Alzheimer's in evoke trials
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1
- CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetes
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4
- Semaglutide (oral): fewer major heart events than placebo in SOUL
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks
- Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UP
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks
- Semaglutide: 24% lower risk of major kidney events in FLOW
- Semaglutide: 10.2% weight loss at 208 weeks in SELECT
- Cagrilintide with semaglutide: 15.6% weight loss in type 2 diabetes
- Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1
- Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT
- Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8
- Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20
- Semaglutide: 35% lower lunch energy intake vs placebo at 20 weeks
- Semaglutide: 14.9% weight loss at 68 weeks in STEP 1
- Semaglutide 2.4 mg: 9.6% weight loss at 68 weeks in STEP 2
- Semaglutide: 16.0% weight loss at 68 weeks with therapy in STEP 3
- Semaglutide STEP 4: -7.9% weight vs +6.9% after switch to placebo
- Tirzepatide beat semaglutide 1 mg on HbA1c at 40 weeks in SURPASS-2
- Semaglutide (oral): heart risk not higher than placebo in PIONEER 6
- Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7
- Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3
- Semaglutide: 6.6% vs 8.9% heart or stroke events in SUSTAIN-6
- Retatrutide: 24.1% weight loss in MC4R-deficient mice over 21 days
- Semaglutide in the library: how it works, half-life and evidence
- Is Semaglutide legal? FDA, DEA and WADA status
- Semaglutide dose guide
Where the reports run ahead of the studies
Weight loss, less appetite, lower blood sugar and an upset stomach are what the controlled trials found too. Where the reports run ahead: 2 of the 41 people, both with long-standing bowel trouble, say their gut settled on semaglutide. No controlled trial has tested semaglutide for irritable bowel; one study of health records has looked at the drug class in it (PubMed, searched November 19, 2026).
Where the reports come from
41 people on 13 pages across 3 sites, written from August 2019 to August 2026. Read on November 19, 2026.
The largest single site, rapamycin.news, gave 23 of the 41.
Peptide Critic, which runs its forum, also runs a shop on its own site that sells injection pens and supplies, not peptides.
Millions of people take semaglutide on a prescription, and the few who write on these forums are a small corner of them who chose to write. The Diabetes UK posters took Ozempic on a prescription for type two diabetes; many rapamycin.news posters took small doses of the Rybelsus tablet for health rather than weight. We read the open threads with the most first-person reports and stopped there.
- rapamycin.news forum, the thread on oral semaglutide (Rybelsus) in healthy people: 14 people
- rapamycin.news forum, the “Experience with GLP-1s” thread: 8 people
- Diabetes UK forum, “3 month Ozempic review”: 4 people
- Diabetes UK forum, a thread on the first weeks of Ozempic: 3 people
- Diabetes UK forum, an Ozempic thread: 2 people
- Diabetes UK forum, an early Ozempic thread: 2 people
- Diabetes UK forum, a thread on a first Ozempic dose: 2 people
- Peptide Critic forum, a thread on a stalled weight loss: 1 person
- Peptide Critic forum, a thread on stacking tirzepatide and retatrutide: 1 person
- Peptide Critic forum, a thread where people tell their weight-loss story: 1 person
- Peptide Critic forum, a newcomer’s introduction: 1 person
- Diabetes UK forum, “New to semaglutide (Ozempic)”: 1 person
- rapamycin.news forum, the “Tirzepatide” thread: 1 person
Read and not counted
- Doctors and clinicians on rapamycin.news who give it to patients: Reports on patients from the people who prescribe it, not a person’s own, so not counted, even where they also wrote of their own use.
- A rapamycin.news member who supplies GLP-1 drugs to clients: The seller’s side of the counter, so not counted.
- Reports about someone else (a cousin, a friend, a wife, a friend’s rat): Second-hand; only a person’s own report counts.
- Posts about price, supply, pharmacies and where to buy: Most posts in these threads; nothing noticed was said.
- Posts where the change could not be put on semaglutide: A poster who could not tell whether night-time trips to the toilet came from the drug or from high blood sugar, and posts naming the drug class without saying which drug.
- Drugs.com user reviews: The site refuses automated reads, so it was skipped.
- Reddit and X: Not part of this count.
How we counted
We read every open write-up we could find by people who took Semaglutide, on its own page, and counted each person once however often they posted, including those who noticed nothing. Sellers, clinics, shop reviews and anyone who earns on a sale are not counted, and neither is a search result’s snippet; the list above names what we read and left out. Write-ups lean positive, because people who notice nothing rarely write about it and expecting an effect can produce one.
Spot an error? feedback@pepvault.app. How we research. This page reports what people say; it is not medical advice.